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Rift Valley fever (RVF) is an emerging viral disease that causes significant human and
veterinary illness in Africa and the Arabian Peninsula. Encephalitis is one of the severe
complications arising from RVF virus (RVFV) infection of people, and the pathogenesis
of this form of RVF is completely unknown. We use a novel reproducible encephalitic
disease model in rats to identify biomarkers of lethal infection. Lewis rats were infected
with RVFV strain ZH501 by aerosol exposure, then sacrificed daily to determine the
course of infection and evaluation of clinical, virological, and immunological parameters.
Weight loss, fever, and clinical signs occurred during the last 1–2 days prior to death.
Prior to onset of clinical indications of disease, rats displayed marked granulocytosis and
thrombocytopenia. In addition, high levels of inflammatory chemokines (MCP-1, MCS-F,
Gro/KC, RANTES, and IL-1β) were detected first in serum (3–5 dpi) followed by brain (5–
7 dpi). The results of this study are consistent with clinical data from human RVF patients
and validate Lewis rats as an appropriate small animal model for RVF encephalitis. The
biomarkers we identified here will be useful in future studies evaluating the efficacy of
novel vaccines and therapeutics.
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INTRODUCTION
Rift Valley fever (RVF) is a multi-dimensional veterinary disease in Africa that causes a highly
fatal disease in livestock (sheep, goats, cattle) as well as illness in people. Mosquitoes are both the
reservoir and vector for RVF virus (RVFV), and yet the virus is also easily transmitted directly
from infected animal tissues. Initially a disease of eastern Africa, RVFV is now found throughout
continental Africa, Madagascar, and the Arabian Peninsula. Importantly, the insect vectors that
transmit RVFV are found in Europe and the Americas, which opens the door to potential
emergence in new locations (Chevalier et al., 2010; Weaver and Reisen, 2010; Hartley et al., 2011;
Konrad and Miller, 2012). The introduction and rapid spread of West Nile Virus (WNV) into the
US in the last 15 years (and Chikungunya virus more recently) serves as a good barometer for the
impact of importation of another mosquito-borne virus such as RVFV. In addition to its potential
as an emerging viral disease, RVFV is listed as a NIAID Category A priority pathogen and is thus
considered a potential bioterror threat due to the ease of infection by inhalation (Department of
Health and Human Services, 2005; United States Department of Agriculture [USDA], 2005).
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During the past 40 years, RVF epidemics have led to signiﬁcant
human morbidity, mortality, and economic damage (Hoogstraal
et al., 1979; Jouan et al., 1989; Balkhy and Memish, 2003). During
large epizootics, humans are exposed to RVFV primarily via
contact with tissues, blood, or inhalation of aerosols released
from contaminated animal carcasses rather than mosquito bite
(van Velden et al., 1977; Hoogstraal et al., 1979; McIntosh et al.,
1980; Anyangu et al., 2010; LaBeaud et al., 2015). A unique
aspect of RVF is that infection of humans can result in a
spectrum of clinical outcomes, including primarily a non-
lethal but debilitating “ﬂu-like” febrile illness, an often-fatal
severe hepatic disease with hemorrhage (“hemorrhagic fever”),
ocular disease/blindness, or delayed-onset meningoencephalitis
(Laughlin et al., 1979; McIntosh et al., 1980; Meegan et al., 1981;
Madani et al., 2003; Mohamed et al., 2010). The true frequency
of occurrence of hemorrhagic fever or encephalitis is diﬃcult
to assess due to inaccuracies in reporting during outbreaks, but
development of either one of these severe forms of RVF carries
a signiﬁcant risk of death. The mechanisms behind the diﬀerent
human clinical outcomes are undeﬁned and represent a void in
our understanding of this emerging viral disease.
Our previous studies suggest that RVFV is more lethal
and more likely to cause neurological disease when infection
occurs by aerosol rather than subcutaneous inoculation (Bales
et al., 2012; Hartman et al., 2014). Prevention or treatment
of severe viral encephalitis is diﬃcult due to the unique
pathogenic mechanisms and relative isolation of the central
nervous system (CNS) from the peripheral tissues. As an
important step in overcoming this hurdle for RVF, we recently
developed the ﬁrst reproducibly lethal neurological diseasemodel
in immunocompetent rats using a wild-type virulent strain of
RVFV (Bales et al., 2012). This model allows, for the ﬁrst
time, detailed study of the mechanisms of neuropathogenesis
caused by RVFV. Here, we performed a pathogenesis experiment
in Lewis rats infected with RVFV by aerosol, with the goal
of better understanding the disease process and identifying
biomarkers indicative of lethal disease. Prior to onset of any
clinical indications of disease, alterations in leukocytes and
inﬂammatory chemokines were detectable in blood samples from
Lewis rats. This study illustrates the utility of the Lewis rat as a
model suitable for studying neurotropic RVF. It is also a crucial
step in the development of eﬀective vaccines and therapeutics to
combat this important emerging viral disease.
MATERIALS AND METHODS
Biosafety and Regulatory Information
Experiments with infectious RVFV-ZH501were performed in the
University of Pittsburgh Regional Biocontainment Laboratory
(RBL) BSL-3/ABSL-3 facilities using safety precautions described
previously (Bales et al., 2012). The University of Pittsburgh RBL
is a Registered Entity with the CDC/USDA for work with RVFV.
Virus Propagation and Culture
Rift Valley fever virus strain ZH501 was kindly provided by Barry
Miller (CDC, Ft. Collins, CO, USA) and Stuart Nichol (CDC,
Atlanta). Prior to receipt, the virus was generated from reverse
genetics plasmids (Bird et al., 2007a) containing the wild-type
ZH501 sequence, which was conﬁrmed by sequencing. Virus
was propagated on VeroE6 cells using standard methods. For
virus quantitation, standard plaque assays were performed using
an agarose overlay (1x minimum essential medium, 2% FBS,
1% penicillin/streptomycin, HEPES buﬀer, and 0.8% SeaKem
agarose), incubated for 3 days at 37◦C, and visualized using
crystal violet. For titration of tissue samples, tissue pieces were
homogenized in 2x volume of DMEM+ 10% FBS using an Omni
tissue homogenizer (Omni International), followed by a standard
plaque assay on the homogenate.
Serial Sacrifice Rat Experiment
All animal work described here was reviewed and approved
by the University of Pittsburgh IACUC. Female Lewis
(LEW/SsNHsd) rats (8–10 weeks old) were obtained from
Harlan Laboratories. All rats were provided rodent food (IsoPro
Rodent 3000) and water ad libitum. Each rat had implantable,
programmable temperature transponders (IPTT-300; Bio Medic
Data Systems, Seaford, DE, USA) inserted subcutaneously
between the shoulder blades for identiﬁcation and temperature
monitoring. Inside a Class III biosafety cabinet or ‘glove box,’
rats were exposed for 10 min in a whole-body aerosol chamber
to small-particle aerosols created by a 3-jet Collison nebulizer
(CH Technologies, Westwood, NJ, USA) controlled by the
AeroMP aerosol exposure control system (Biaera Technologies,
Hagerstown, MD, USA; Reed et al., 2014). Air sampling and
dose calculation were done as previously described with an
all-glass impinger (Bales et al., 2012; Reed et al., 2014). Prior to
aerosolization, the virus was diluted to the desired concentration
in DMEM containing 2% FBS, penicillin-streptomycin, 10 mM
HEPES buﬀer, 0.1% Antifoam-Y emulsiﬁer, and 0.1% glycerol.
The infected rats received an inhaled (presented) dose of
2.5 × 104 pfu/animal (>LD99; Bales et al., 2012). Body
temperature and weight were recorded daily, and each animal
was monitored at least twice daily for the development of clinical
signs. Each day following infection, 3–4 rats were randomly
chosen and euthanized for collection of samples. For each rat,
blood was drawn by cardiac puncture immediately prior to
euthanasia. During necropsy, a portion of each tissue was frozen
for determination of viral load by plaque assay, and a second
piece of each tissue was ﬁxed in 10% neutral buﬀered formalin
for 2 weeks prior to removal from the BSL-3 facility. Fixed
tissues were processed for histology as described (Hartman et al.,
2014). The pathologist was blinded when scoring samples for
the degree of pathological changes. Blood samples were used for
measurement of complete blood counts (CBC; VetScan HM2;
Abaxis) and the comprehensive diagnostic blood chemistry
panel (VetScan VS2; Abaxis). Serum was harvested and used
for measuring RVF-speciﬁc antibody responses as described
(Caroline et al., 2014). Serum and clariﬁed homogenized brain
tissue were used to measure cytokine levels using the Bio-
Plex Pro Rat Cytokine 23-plex assay (Bio-Rad). The analytes
measured were EPO, G-CSF, GM-CSF, GRO/KC, IFN-γ, IL-1α,
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p70, IL-13, IL-17A,
IL-18, M-CSF, MCP-1, MIP-1α, MIP-3α, RANTES, TNF-α, and
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VEGF. Virus speciﬁc IgG ELISA was performed as described
(Caroline et al., 2014).
RNA Extraction and Real-Time Taqman
RT-PCR
A semi-quantitative RT-PCR assay was used to measure viral
RNA copies in rat samples. Prior to RNA extraction, tissues were
homogenized as described above. Samples were inactivated for
RNA extraction using Tri Reagent (Ambion) prior to removal
to a lower biosafety level. Serum or tissue homogenate was
mixed with Tri Reagent (1:10 ratio) for the virus inactivation
step. This procedure was validated using a safety test as
described previously (Blow et al., 2004) to ensure inactivation
of RVFV, and the validated procedure was approved by the
RBL Biosafety Oﬃcer. For the safety test, 100 ul of virus
stock (equivalent to 1 × 106 pfu) was added to 900 ul
Tri Reagent. The sample was mixed thoroughly by vortexing
and allowed to sit for 5 min at room temperature. After
the 5 min incubation, the entire sample was transferred to
a new, sterile microcentrifuge tube. 100 ul of the virus-Tri
Reagent mix was removed to be used for plaque assay. To
the virus-Tri Reagent mix, 200 ul chloroform was added,
the sample was centrifuged 12,000 × g for 15 min, and the
aqueous phase was removed. 100 ul of the aqueous phase
was used for plaque assay. Plaque assays on VeroE6 cells
were performed using 10-fold dilutions (10−1–10−6) of the
virus-Tri Reagent homogenate, the aqueous phase sample, and
appropriate controls (including vehicle controls for the Tri
Reagent and aqueous phase, and a positive control using spiked
virus stock (1 × 106 pfu)). Toxicity from the Tri Reagent
and chloroform were seen at 10−1 and 10−2 dilutions. No
cell death or plaques were seen at higher dilutions in any
of the samples, and plaques were visible in the 10−5 and
10−6 dilutions of the positive control. Safety test indicated
that viral titers were reduced at least 3–4 logs. RNA was
extracted from serum samples using a combination of the Tri
Reagent protocol and the PureLink Viral RNA/DNA extraction
kit (Invitrogen). For tissue samples Tri Reagent and the RNeasy
Mini Kit (Qiagen) were used. The SuperScript III Platinum
One-Step Quantitative RT-PCR Kit (Invitrogen) was used for
ampliﬁcation of 5 ul of each RNA sample. Primers, probe,
and cycling conditions used for RVFV real-time RT-PCR were
followed as described (Bird et al., 2007b). A standard curve was
generated using 10-fold dilutions of RNA from virus stock of
known titer (pfu). Data are expressed as pfu equivalents per
ml or g.
RESULTS
Clinical Illness and Behavior
When Lewis rats are exposed to small particle aerosols of RVFV
ZH501, they succumb to a lethal neurological illness within 6–
8 days post-infection (Bales et al., 2012). In order to better
understand the pathogenesis caused by RVFV after aerosol
exposure, Lewis rats were infected with 25,000 pfu (equivalent to
the LD99) of RVFV by aerosol exposure. Temperature and weight
were monitored daily (Figure 1). On 1–7 days post-infection
(dpi), three or four rats were selected for euthanasia daily.
Weight loss and fever were not evident until end-stage
disease at 5 and 6 dpi, respectively (Figure 1). Rats did not
demonstrate overt clinical signs until 6 and 7 dpi as well.
Typical signs of illness included decreased activity, scruﬀy
appearance, hunched posture, half-closed eyes, and porphyrin
staining around the eyes, nose, or mouth. Neurological signs
appeared during this time frame and included one or more
of the following: (1) circling in cage, (2) horizontal rolling,
and (3) head tilt or abnormal tremors of the head and
neck. Occasionally an infected rat will display abnormally
erratic behavior (uncontrolled jumping within cage) instead of
decreased activity or lethargy. Seizures or paralysis have not been
seen in RVFV-infected Lewis rats. Seroconversion occurred at
FIGURE 1 | Weight loss and temperature changes in Rift Valley fever virus (RVFV)-infected Lewis rats. Changes in (A) body weight, (B) temperature over
the duration of the experiment. The gray shaded box on both graphs represents the window of clinical disease (5–7 dpi).
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FIGURE 2 | Virus dissemination over time. Virus was measured in the indicated tissue by plaque assay (solid squares; pfu/g tissue) or taqman RT-PCR (open
circles; pfu equivalents/g tissue). Horizontal line on each graph represents the limit of detection of the plaque assay (50 pfu). The gray shaded box on all graphs
represents the window of clinical disease (5–7 dpi). For (A–C,F), the M on the x-axis stands for ‘moribund’ and represents historical samples from previous Lewis rat
experiments (correspond to 7–8 dpi). Tissue samples were taken at the time the rat was moribund and are included here for comparison purposes. These samples
are not available for (D) and (E).
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6 dpi and later, as measured by virus-speciﬁc IgG antibodies (data
not shown).
Kinetics of Virus Replication and
Dissemination
To determine the kinetics of virus replication and dissemination
in rats after aerosol exposure, viral load in various tissues was
measured by both plaque assay and semi-quantitative Taqman
RT-PCR. Moderate levels (104–106 pfu/g) of infectious virus
persisted in the lung from 1 to 5 dpi, with a peak occurring at
3 dpi. Virus in the lung decreased to undetectable levels in most
rats by 7 dpi (Figure 2A). Despite the persistent presence of virus,
there was little to no pathological damage to the lung tissue (data
not shown). Taqman RT-PCR to measure viral RNA (expressed
as pfu equivalents) paralleled the plaque assay results.
The liver and spleen are both primary targets of virus
replication in livestock infected with RVFV, as well as in
most other rodent models of hepatic RVF disease. High virus
replication and signiﬁcant pathology typically occurs in both
tissues (Smith et al., 2010; Bales et al., 2012; Gray et al.,
2012). In contrast, the Lewis rat neurological model examined
here displayed low levels (102–103 pfu/g) of infectious virus
transiently in the liver and spleen of only a few of the rats
at 3 and 4 dpi (Figures 2C,D), and similarly small amounts
of viral RNA were detectable at earlier and later time points.
No pathological changes were observed in either liver or spleen
tissue (data not shown). Liver damage was minimal, as measured
by the liver enzymes alanine transaminase (ALT) and alkaline
phosphatase (ALP) in the blood (Figure 7). Transient, low-level
viremia was seen in a few rats on 2 and 3 dpi, but viral RNA
was not detectable at additional time points, indicating viremia
was mild in these rats (Figure 2F). These data are evidence
of systemic virus replication, even if very limited as compared
to hepatic disease models. Interestingly, low levels of infectious
virus were detectable in the eyes, with all rats sacriﬁced at 7 dpi
having detectable infectious virus (Figure 2E). There was also
evidence of low levels of viral RNA in the eyes as at earlier time
points.
This is in stark contrast to brain, which is clearly the
primary tissue targeted in the Lewis rat model (Figure 2B).
Infectious virus was not detectable in brain until 5 dpi, at
which point high levels (107–109 pfu/g) are seen for the
duration of illness (Figure 2B). Very low levels of viral
RNA were detectable at earlier time points before 5 dpi,
however, only detection of infectious virus was associated
with signiﬁcant pathology (Table 1). Mild pathological
lesions began to appear in a few rats at 4 dpi progressing
to considerable lymphocytic meningitis (Figures 3A–C),
vasculitis composed of lymphocytes, histiocytes, and neutrophils
(Figure 4), as well as cortical neurons with apoptotic
morphology in all of the rats by 6 and 7 dpi (Figures 3D,E
and 5). Immunohistochemistry (IHC) revealed extensive
viral antigen expression within neurons of the submeningeal
cortex (Figures 3B,C,F and 5B). Viral antigen expression
was associated with phenotypically apoptotic cells, and no
inﬂammatory inﬁltrate was seen in association with these
cells (Figure 5). Immune inﬁltrate in areas of meningitis and
TABLE 1 | Pathological lesions in brain tissue of Rift Valley fever virus
(RVFV)-infected Lewis rats.
Day
euthanized
# Rats displaying
pathology
Description of pathological lesions
1 0/3 None
2 0/3 None
3 0/3 None
4 2/4 Focal mild lymphocytic meningitis
5 1/4 Focal meningeal thickening
6 3/3 Lymphocytic meningitis; vasculitis containing
lymphocytes, histiocytes, and neutrophils; focal
cortical apoptosis; focal RVFV Ag+ cells in
cortex
7 3/3 Lymphocytic meningitis; vasculitis containing
lymphocytes, histiocytes, and neutrophils;
apoptosis of the subcortical neurons; extensive
RVFV Ag+ cells in cortex
vasculitis were not positive for virus antigen by IHC staining,
suggesting that it is unlikely that these cells are productively
infected.
Kinetics of Cellular Changes in the Blood
Complete blood counts (CBCs) performed on each rat showed a
transient but signiﬁcant drop in lymphocyte numbers on 3 dpi
(60% decrease; p = 0.04 by t-test; Figure 6, arrow). By 4 dpi,
platelet counts dropped to at or below 200 × 1012 cells/l for
the duration of the infection, indicative of thrombocytopenia.
By 6 and 7 dpi, platelets numbers were 1/10th of the baseline
levels (p = 0.0015 by ANOVA). However, no diﬀerences
in overall blood clotting times were seen (as measured by
PT and aPTT; data not shown). In contrast to platelets,
granulocyte numbers increased signiﬁcantly over baseline from
4 dpi onwards and were 10-fold above baseline by 7 dpi
(p < 0.0001 by ANOVA; CTL signiﬁcantly diﬀerent from 4,
5, 6, and 7 dpi by multiple comparison test). Blood chemistry
analysis (14-parameter) was also performed at each time point,
but no signiﬁcant changes were seen over the course of
infection, including ALT and ALP, indicating the liver and
kidney damage were not prominent features of this disease
(Figure 7).
Cytokine Dysregulation
A multiplex assay was used to measure cytokines and
chemokines in serum and brain tissue over the course of
infection. Out of 23 cytokines/chemokines analyzed, ﬁve
showed signiﬁcant expression changes in both serum and
brain (Figure 8), while another eight were dysregulated only
in the brain (Figure 9). None of the cytokines/chemokines
analyzed were dysregulated only in serum. Statistical
signiﬁcance was determined by ANOVA with multiple
comparison tests for each time point compared to uninfected
controls.
In serum, increases were observed in levels of MCP-
1 (CCL2; p < 0.0001), M-CSF (p = 0.001), Gro/KC (IL-
8/CXCL1; p = 0.004), RANTES (CCL5; p = 0.05), and IL-
1β (p = 0.002) (Figure 8). Between 3 and 5 dpi, MCP-1,
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FIGURE 3 | Histologic images of the brain of RVFV-infected Lewis Rats. (A) H&E; Rat R819 taken 7 dpi; low magnification showing lymphocytic meningitis
with apoptosis of the subcortical neurons. (B) IHC; Rat R819 taken 7 dpi; RVFV Ag+ cells (reddish/brown staining) in the cortex with lymphocytic meningitis.
(C) IHC; Rat R818 taken 7 dpi; low magnification illustrating the large number of RVFV Ag+ cells in the cortex with marked lymphocytic meningitis. (D) H&E; Rat
R819 taken 7 dpi; high magnification of subcortical cells with characteristic appearance of apoptosis (arrows). (E) H&E; Rat R821 taken 6 dpi; subcortical cells with
characteristic appearance of apoptosis (arrows). (F) IHC; Rat R818 taken 7 dpi; high magnification of RVFV Ag+ cells in cortex.
M-CSF, and Gro/KC were all highly upregulated. The most
signiﬁcant alteration found in serum was expression of the
chemokine MCP-1. Increased levels were seen starting at 3 dpi
and peaking at 4 dpi in serum, followed by a decrease to
baseline levels by day 7 (Figure 8A). The peak at 4 dpi was
ﬁvefold greater than baseline expression levels. M-CSF levels
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FIGURE 4 | Vasculitis in the brain of RVFV-infected Lewis rats. (A) H&E; Rat R821 taken 6 dpi; vasculitis consisting of lymphocytes (thin arrows), area of
concentrated histiocytes (thick arrow), and area of concentrated neutrophils (arrowhead). (B) H&E; Rat R818 taken 7 dpi; vasculitis with lymphocytes, histiocytes,
and neutrophils. Large number of neutrophils are seen in the bottom half of the photo.
in serum were also signiﬁcantly elevated at 3 and 4 dpi, then
returned to baseline (Figure 8C). For Gro/KC, there was a
two–fourfold increase in expression levels in serum at 4 dpi
(Figure 8E).
Signiﬁcant changes in RANTES and IL-1 β were also seen
in serum samples, although the changes were less dramatic
(Figures 8G,I). RANTES expression occurred in a biphasic
pattern, ﬁrst a 1 dpi (2.5-fold increase) and then another peak
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FIGURE 5 | Apoptotic morphology of cortical neurons. Rat R818 taken 7 dpi. (A) H&E; cerebral cortex with morphologically apoptotic cells (asterisks). (B) IHC;
RVFV Ag+ neurons in the cerebral cortex, two with apoptotic appearance (asterisks).
later in infection at 5–6 dpi (ﬁvefold increase). IL-1β showed
peaks in expression at 4 dpi and again at the last time point,
7 dpi. Aside from RANTES, expression of MCP-1, M-CSF,
Gro/KC, and IL-1 β all peaked at 4 dpi, suggesting that this is
an important time point. There were no signiﬁcant changes in
serum expression levels of IFN-γ, TNF-α or any other analyte
measured.
Measuring the levels of the same proteins in homogenized
brain samples provided another dimension to the disease process
in Lewis rats. While serum displayed alterations in the 3–5 dpi
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FIGURE 6 | Changes in blood cells over the course of infection. The arrow represents a significant decrease in blood lymphocytes at that time point, as
measured by t-test. The black box represents the time point at which both granulocytes and platelets differ significantly from controls (as measured by ANOVA with
multiple comparison test), and these differences persist through the end of infection. The gray shaded box represents the window of clinical disease (5–7 dpi).
FIGURE 7 | Liver metabolic enzymes during the course of RVFV
infection of Lewis rats. 14-parameter blood chemistry analysis was
performed on each rat at the time of sacrifice. Alanine transaminase (ALT; a
marker of liver cell damage) and alkaline phosphatase (ALP; produced by liver
cells) are shown. Significance was evaluated using one-way ANOVA and no
significant differences over time were found (p = 0.1 and p = 0.08 for ALT and
ALP, respectively).
window, expression levels in brain samples occurred during the
5–7 dpi window of clinical disease. Elevations of MCP-1 (four–
sixfold; p = 0.005), M-CSF (p = 0.001), Gro/Kc (two–fourfold;
p = 0.01), RANTES (p = 0.02), and IL-1β (p< 0.0001) were seen
during this time (Figure 8).
An additional eight chemokines were diﬀerentially expressed
in brain tissue but not in serum (Figure 9). There was a
notable peak in expression level at 5 dpi for seven of these eight
cytokines. These included pro-inﬂammatory cytokines such as
IL-18 (p = 0.002), IL-1α (p = 0.02), EPO (p = 0.002), IFN-
γ (p = 0.02), VEGF (p = 0.002), chemotactic protein MIP-3α
(p = 0.03), and anti-inﬂammatory cytokine IL-10 (p = 0.02). IL-
13, also thought to be an anti-inﬂammatory cytokine, decreased
signiﬁcantly in the brain on 4 dpi (p = 0.04). In summary, we
detected dysregulation of cytokines and chemokines in the serum
(3–5 dpi) and brain (4–7 dpi), with more extensive dysregulation
occurring in brain tissue.
DISCUSSION
While RVF was recognized as a veterinary illness since the
1930’s, the human illness remains rather enigmatic. The primary
human disease caused by RVFV is a febrile illness that can
be debilitating for several days but not lethal, and only a
handful of human deaths were attributed to RVFV prior to
1975 (Laughlin et al., 1979). In South Africa during that year,
70–80 deaths were reported, with at least 15 cases of encephalitis
among them (van Velden et al., 1977; McIntosh et al., 1980).
Then an unexpected and large epidemic occurred in Egypt
(1977–1979) that changed the paradigm of RVF in humans.
For the ﬁrst time, signiﬁcant human morbidity and mortality
were observed (estimated at 200,000 human infections; 600
deaths; Laughlin et al., 1979; Meegan, 1979). The human clinical
manifestations included such disparate illnesses as hemorrhagic
disease, encephalitis, and ocular disease. RVF remains unique in
that it causes such distinct clinical outcomes, and themechanisms
behind this observation are unknown. Epidemics of RVF since
the 1970’s have been characterized by an overall increase in
human morbidity and mortality, including patients presenting
with neurological symptoms (Al-Hazmi et al., 2003;Madani et al.,
2003; Mohamed et al., 2010).
Rift Valley fever virus is an overlap Select Agent regulated by
both the CDC and APHIS (Department of Health and Human
Services, 2005; United States Department of Agriculture [USDA],
2005). It is also a NIAIDCategory A priority pathogen and is thus
considered a potential bioterror threat due to the ease of infection
by inhalation (Department of Health and Human Services, 2005;
United States Department of Agriculture [USDA], 2005). For
these reasons, the U.S. Department of Defense has funded studies,
including this one, to develop animal models after inhalational
exposure to RVFV.
The majority of experimental work with RVFV has been
performed in mice, which predominately develop lethal hepatic
disease but also occasionally develop delayed-onset encephalitis
after infection with RVFV by the subcutaneous route (do Valle
et al., 2010; Smith et al., 2010; Gray et al., 2012; Dodd et al.,
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FIGURE 8 | Cytokine and chemokine dysregulation in serum and brain of RVFV-infected Lewis rats. Serum and homogenized brain tissue were analyzed
using the Bio-Plex Pro Rat Cytokine 23-plex assay. All analytes were tested for significance using one-way ANOVA. The five cytokines shown in this figure were
statistically significant for both serum (left column) and brain (right column). The level of significance by ANOVA is reflected by the number of asterisks on each graph
title, where ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, ∗∗∗∗ p ≤ 0.0001. Individual time points were compared to uninfected controls by t-test. Significant time points are
indicated by the black box. The gray shaded box on all graphs represents the window of clinical disease (5–7 dpi).
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FIGURE 9 | Cytokine and chemokine dysregulation in the brain of RVFV-infected Lewis rats. The eight cytokines shown in this figure were statistically
significant in brain but not serum. The level of significance by ANOVA is reflected by the number of asterisks on each graph title, where ∗p ≤ 0.05, ∗∗p ≤ 0.01,
∗∗∗p ≤ 0.001, ∗∗∗∗p ≤ 0.0001. Individual time points were compared to uninfected controls by t-test. Significant time points are indicated by the black box. The gray
shaded box on all graphs represents the window of clinical disease (5–7 dpi).
Frontiers in Microbiology | www.frontiersin.org 11 January 2016 | Volume 6 | Article 1509
Caroline et al. Biomarkers of Rift Valley Fever
FIGURE 10 | Course of neurological disease in RVFV-infected Lewis rats. Timing of clinical and virological events after aerosol exposure to RVFV. The clinical
window is from 5 dpi until death of the rat, and consists of behavioral and appearance changes, weight loss, and fever. Rats succumb to disease between 6 and
8 dpi. Cytokine/chemokine dysregulation in the blood starts as early as 1 dpi (RANTES) and extends to 5 dpi (MCP-1, M-CSF, and Gro/KC). Changes in CBC start
at 4 dpi and persist throughout infection. Live virus is found in the brain from 5 dpi onwards, along with significant pathology and cytokine/chemokine dysregulation.
Virus-specific antibody responses are not apparent until 6 dpi.
2013; Gowen et al., 2013). Since hepatic disease is generally the
outcome after infection of mice, understanding the pathogenesis
of neurological form of RVF has been diﬃcult. Consistent
encephalitis can be induced in mice when intranasally infected
with a recombinant virus lacking the NSs protein (delNSs virus;
Dodd et al., 2013, 2014). However, delNSs virus is attenuated
in rats (Bird et al., 2008). RVFV deleted for the NSm protein
(delNSm virus) caused encephalitis in 17% of infected Wistar-
Furth rats (Bird et al., 2007a). Gerbils were found to have an
age-dependent susceptibility to neuroinvasive RVF, but even at
the highest doses administered subcutaneously (107 pfu), 50% of
the gerbils survived infection (Anderson et al., 1988). The lack of
a consistent neurological disease rodent model using moderate
doses of wild type virus has thus far hampered investigations into
the neuropathogenesis of RVF.
Our studies in rats and monkeys have shown that RVFV
is more lethal and more likely to cause neurological disease
when administered by aerosol rather than subcutaneous infection
(Bales et al., 2012; Hartman et al., 2014). This ﬁnding, along
with an increase in RVF encephalitis in the past 40 years and
the potential for a terrorist or rogue nation to use an inhaled
formulation as a bioweapon, make an understanding of the
pathogenesis of RVF encephalitis of paramount importance.
To this end, we have developed the ﬁrst reproducibly lethal
neurological disease model in immunocompetent rats using a
wild-type virulent strain of RVFV (Bales et al., 2012).
This study provides detailed description of the clinical
neurological disease that develops in Lewis rats exposed to
aerosols containing virulent RVFV (Figure 10). The clinical
window is narrow; observable signs of illness, weight loss, and
fever occur within the last 24–48 h preceding death. This
restricted window makes evaluation of the eﬃcacy of novel
vaccines and therapeutics more diﬃcult.
With respect to virus dissemination, we found evidence
of limited peripheral virus replication. The brain was clearly
the primary target, with high levels of infectious virus in the
brain during the clinical window that correlated with signiﬁcant
pathological damage. Expression of viral antigen in neurons of
the cerebral cortex was extensive, with some neurons having
the morphological appearance of apoptotic cells. Meningitis, and
vasculitis comprising lymphocytes, monocytes, and neutrophils
were the primary pathological lesions; this immune inﬁltrate did
not appear to be infected based on viral antigen detection. Virus
persisted in the lung without causing signiﬁcant pathology.
A distinctive ﬁnding was the presence of infectious virus and
viral RNA in eye samples, with all the rats testing positive at end-
stage disease. Ocular disease is an important manifestation of
RVF in humans (Laughlin et al., 1979; Siam et al., 1980). Retinitis
can be bi- or uni-lateral, may be associated with exudate or
hemorrhage (Siam andMeegan, 1980), and can lead to temporary
or permanent vision loss. The Lewis rat modelmay provide future
insights into this aspect of RVF.
Despite the narrow clinical window, we have identiﬁed earlier
parameters (biomarkers) that are associated with lethal disease
(Table 2). Changes in blood cells began with a transient decrease
in lymphocytes at 3 dpi, followed by sustained granulocytosis
and thrombocytopenia from 4 dpi onwards. These ﬁndings
have some overlap with what is known about human RVF.
Thrombocytopenia has been documented in clinical samples
TABLE 2 | Biomarkers indicative of lethal neurological RVF in Lewis rats.
Biomarker Time point (dpi)
Cytokines/chemokines in serum:
↑ RANTES 1
↑ MCP-1 3–5
↑ M-CSF 3–4
↑ Gro/KC 4
Blood cell parameters:
↓ Lymphocytes 3
↑ Granulocytes 4–7
↓ Platelets 4–7
Clinical indications:
Fever 6–7
Weight loss 6–7
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from RVF-infected patients, although a distinction was not
made between patients with hemorrhagic or neurological disease
(van Velden et al., 1977; Madani et al., 2003; McElroy and
Nichol, 2012). Neutrophils are a prominent component of the
inﬂammation in brains of RVFV-infected calves (Rippy et al.,
1992). We found not only granulocytosis in the blood, but
neutrophil inﬁltration in the brain of infected rats.
Changes in inﬂammatory markers in the serum involved ﬁve
chemokines (MCP-1, M-CSF, Gro/KC, RANTES, and IL-1β) and
occurred transiently from 3–5 dpi and preceded similar increases
in brain (5–7 dpi), indicating that these chemokines may be
actively recruiting monocytes, macrophages, and neutrophils
into the CNS. Alternatively, changes in serum expression levels
may be related to peripheral virus replication in the lung,
liver, and spleen. MCP-1, RANTES, and Gro/KC have been
implicated in inﬂammation of the brain in other viral encephalitic
diseases, including tick borne encephalitis (TBE), Semliki forest
virus (SFV), and West Nile virus (WNV) (Ruzek et al., 2011;
Michlmayr et al., 2014). Recently, human serum samples from
cases of RVF were analyzed for levels of inﬂammatory cytokines.
In this study, serum levels of MCP-1, RANTES, and IL-
8/GroKC were implicated in fatal human cases (van Vuren
et al., 2015). In addition, our study here found no alterations
in expression of TNF-α, IFN-γ, IL-6, IL-10, or IL-12 in serum
from infected rats, which ﬁts with previous studies indicating
that the NSs protein can inhibit expression of these cytokines
in human cells and patient samples (McElroy and Nichol,
2012).
Cytokine/chemokine derangement in the brain was more
extensive than in serum. The most signiﬁcant changes
in the brain involved MCP-1, RANTES, and Gro/KC, as
described above, which correlated with serum. However,
other cytokines/chemokines were increased in expression
in the brain only. There was a signiﬁcant peak in
expression of IL-1α, IL-10, IL-13, IL-18, IFN- γ, EPO,
VEGF, and MIP-3a at 5–6 dpi, which coincides with
pathology, viral load, and clinical illness. The relationship
between peripheral cytokines in the serum, brain, and virus
replication in both locations remains a focus of ongoing
studies.
MCP-1 is an important mediator of inﬂammation of
the CNS in a number of disease models, including viral
encephalitis, and is even a source of potential intervention.
A potent chemoattractant of monocytes, it is produced
by a variety of cell types, including neurons, astrocytes,
and microglia in the brain, along with endothelial cells,
epithelial cells, ﬁbroblasts, and monocytes/macrophages. Serum
MCP-1 levels have been implicated as a marker for brain
tissue injury in HIV-infected patients (Ragin et al., 2006),
and is elevated in HIV patients with CMV encephalitis
(Bernasconi et al., 1996). Gro/KC (CXCL1 and IL8 homolog)
is chemoattractant for neutrophils, and may explain the
granulocytosis in the blood and inﬁltration of neutrophils
into the CNS. It has been implicated in HHV-6 encephalitis
(Kawabe et al., 2010). RANTES and IL-8 levels increased
in CSF in patients with JEV encephalitis (Kalita et al.,
2010).
Using virulent, wild-type RVFV, immunocompetent Lewis
rats, and an aerosol exposure method, we induced lethal
encephalitis and documented the course of neurological
disease. The virus disseminates throughout the body but
is limited in peripheral replication. We show that lethal
disease is accompanied by inﬂammatory mediators evident
in the serum before the onset of clinical disease, followed
by inﬂammatory derangement in the brain during clinical
illness. Limited information from human clinical samples
suggest that the Lewis rat model has some similarities
with human cytokine data, although further studies are
required determine if cytokine changes are associated with
human RVF disease in general or a particular human
clinical outcome, such as encephalitis or hemorrhagic disease.
The biomarkers we identiﬁed here in the Lewis rat model
will be useful in future studies evaluating the eﬃcacy
of novel vaccines and therapeutics in these rodents. In
addition, further studies comparing inﬂammatory cytokine
expression in subcutaneously infected Lewis rats compared
to those infected by aerosol in this study will determine the
predictive capacity of these biomarkers in relation to exposure
route.
In summary, this study represents an important ﬁrst step in
understanding the mechanisms of neurovirulence of RVFV in the
rat model. Further studies are underway to understand the route
of neuroinvasion and the contributions of immunopathogenesis
to RVF disease.
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